Mytesi may provide a solution for noninfectious diarrhea in PLWH on ART
Mytesi is a nonopiate, antisecretory medication that normalizes fluid and electrolyte balance in the gastrointestinal (GI) tract and provides symptomatic relief of diarrhea with a minimal risk of constipation.2-4
Mytesi demonstrated a significant decrease in diarrhea in the ADVENT clinical trial.2-4
There were no treatment interruptions or discontinuations due to Mytesi-related adverse events in clinical studies.2-4
*Subject to eligibility. Restrictions apply. Rx only.
References:
1. Online Survey of Patients Living with HIV (2017). Sponsored by Napo Pharmaceuticals. 2. Mytesi [package insert]. San Francisco, CA: Napo Pharmaceuticals. 2018. 3. MacArthur RD, Clay P, Blick G, Waltzman R, Bell M. Long-term Crofelemer provides clinically relevant reductions in HIV-related diarrhea. 9th IAS Conference on HIV Science (IAS 2017), July 23-26, 2017, Paris, France. Abstract WEPEB0537. 4. MacArthur R, Harkins TN, Brown SJ, et al. Efficacy and safety of Crofelemer for non-infectious diarrhea in HIV-seropositive individuals (ADVENT Trial): a randomized, double-blind, placebo-controlled, two-stage study. HIV Clin Trials. 2013;14(6):261-273. 5. Hardwicke RL, Guthrie E, Chen HY, Grimes RM. Has diarrhea ceased to be a concern in persons living with HIV? Results from a cross-sectional study. J Assoc Nurses AIDS Care. 2021;32(5):e40-e45. doi:10.1097/JNC.0000000000000204